Navigation Links
Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease
Date:6/18/2013

SYDNEY, Australia And EMERYVILLE, Calif., June 18, 2013 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. presented final results today from a Phase 2/3 clinical trial of ADS-5102 (amantadine HCl extended release) capsules demonstrating a statistically significant improvement in levodopa-induced dyskinesia (LID) as measured by change from baseline at week 8 versus placebo in the Unified Dyskinesia Rating Scale (UDysRS). ADS-5102 is Adamas' investigational extended-release formulation of amantadine intended for once-nightly administration that is being studied for the treatment of LID in Parkinson's disease (PD) patients. Data from the Phase 2/3 EASED™ (Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia) clinical trial were presented today at the 17th International Congress of Parkinson's Disease and Movement Disorders.

(Logo: http://photos.prnewswire.com/prnh/20130618/LA33709LOGO)

"For Parkinson's disease patients suffering from the dyskinesia side effects of levodopa treatment, reducing the time and severity of these effects has been a long-term goal in their treatment. ADS-5102 demonstrated a significant reduction in the duration and severity of troublesome dyskinesia among PD patients with levodopa-induced dyskinesia in this well-designed, controlled clinical study," said Rajesh Pahwa, M.D., Professor of Neurology, University of Kansas Medical Center and an investigator for the EASED study. "The clinical results seen in this study of ADS-5102 are extremely encouraging and have the potential to make a difference in patients' lives," Dr. Pahwa added.

The EASED study of ADS-5102 met its primary endpoint; both the 340 mg and 420 mg ADS-5102 dose levels significantly reduced LID as measured by the change in UDysRS Total Score over eight weeks versus
'/>"/>

SOURCE Adamas Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Adamas Pharmaceuticals To Report Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia In Parkinsons Disease
2. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
3. Isis Pharmaceuticals to Present a General Corporate Update at its 2013 Annual Meeting of Stockholders and Open House
4. Valeant Pharmaceuticals Announces Public Offering Of Common Shares
5. Perrigo Company Acquires Ophthalmic Product Portfolio From Fera Pharmaceuticals, LLC For An Upfront Payment Of $93 Million
6. Johnson & Johnson Announces Definitive Agreement To Acquire Aragon Pharmaceuticals, Inc.
7. Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property Assets from Buderer Drug Company
8. Intercept Pharmaceuticals Announces Proposed Public Offering of Common Stock
9. Chronische Nierenerkrankung: Das Risiko des Fortschreitens reduzieren -- Prismic Pharmaceuticals sichert sich exklusive Lizenzrechte
10. Imprimis Pharmaceuticals, Inc. to Present at the National Investment Banking Association (NIBA) Conference June 18th in New York City
11. Conatus Pharmaceuticals Inc. Files Registration Statement for Proposed Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 24, 2014 /PRNewswire/  -- Tianyin Pharmaceutical Inc. ... company that specializes in the patented biopharmaceutical, modernized ... pharmaceutical ingredients (API) released unaudited preliminary financial results ... Fiscal Year 2015 Ended September 30, ... million compared with $14.7 million in 1Q14 with ...
(Date:12/24/2014)... -- The International Trade Commission (ITC) issued its final decision in ... a notice issued on December 23, the ITC ruled in ... humidifier was invalid. BMC President, James Xu ... excited with the ITC,s decision in this case. This victory ... the very beginning on the key patents in the case. ...
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, 2014 ... a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics ... medical need and commercial potential, today announced that ... 2,050,000 shares of its common stock and Series ... common stock.  Funds under the management of QVT ...
Breaking Medicine Technology:TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4
... SEATTLE, Jan. 31, 2012 /PRNewswire-iReach/ -- Today ... the launch of new last mile postal service delivery ... software. In addition to existing support of multiple global ... cost-effective delivery capabilities to businesses and residences in over ...
... 2012 Vystar Corporation (OTCBB: VYST), the exclusive ... third US and first Chinese patent for its ... five issued patents in the US and abroad that relate ... (Logo: http://photos.prnewswire.com/prnh/20100203/CL48049LOGO ) The new ...
Cached Medicine Technology:Enroute Adds Last Mile Postal Service Delivery Services 2Enroute Adds Last Mile Postal Service Delivery Services 3Vystar® Corporation Receives its Third US Patent and First Chinese Patent for Vytex® Natural Rubber Latex 2Vystar® Corporation Receives its Third US Patent and First Chinese Patent for Vytex® Natural Rubber Latex 3
(Date:12/24/2014)... York (PRWEB) December 24, 2014 ... ) that allege the blood thinner caused life-threatening ... outlined a leadership structure for the proceeding, Bernstein ... December 17th, the Court plans to select lawyers ... and also plans on appointing a Plaintiffs’ Steering ...
(Date:12/24/2014)... 2014 Mike Billings , PT, ... Derek Fenwick, PT, MBA, GCS, Director of Professional ... from the passing of the Improving Medicare Post-Acute ... this taping of the Infinicast, the two leaders discuss ... Social Security Act to standardize post-acute assessment data for ...
(Date:12/24/2014)... -- Hepatitis C infection does not contribute to mental decline ... Treatment advances have made it possible for people with HIV ... problems, mood swings and other types of mental impairment as ... long-term infections with other viruses -- a common problem in ... the prime suspects has been the hepatitis C virus, which ...
(Date:12/24/2014)... HealthDay Reporter WEDNESDAY, Dec. ... to start smoking or drinking with each additional symptom ... disorder, new research suggests. "Our findings underscore ... substance use as [these] children approach adolescence," said study ... Research Group, which is part of Cincinnati Children,s Hospital. ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 For chic ladies, ... year. As a part of their Holiday Wish List, ... highlight as perfect ways to accent ladies’ holiday wardrobe by ... Ladies should be all over the discount of 80% off, ... and ready to ship. The company’s chic wedding dresses are ...
Breaking Medicine News(10 mins):Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3Health News:Latest Episode of Infinicast Features Infinity Rehab President Discussing IMPACT Act of 2014 and Changes for Post-Acute Therapy Providers in 2015 2Health News:Hepatitis C Infection Isn't Related to HIV Brain Woes: Study 2Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 2Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 3Health News:Angeldress.co.uk Starts Its Big Sales by Offering Various Kinds of Cheap Clothes and Fashion Accessories 2
... medications are at an increased risk of falling in the ... dose increase of their current drug, according to a new ... an affiliate of Harvard Medical School., Published online in the ... that nursing home residents have a fivefold increased risk of ...
... in California hospitals to similar hospitals in the U.S. ... Pennsylvania School of Nursing have found that controversial legislation ... hospital staffing mix, not fewer as feared. , ... staffing levels. However, mindful of the ongoing nurse shortage ...
... July 15 (HealthDay News) -- Injection drug users have ... what types of drugs they use, according to a ... higher rates of abuse, dependence and other physical and ... programs specialize their care to target these high-risk individuals. ...
... of consent forms provided to volunteers for HIV/AIDS research ... risks and benefits has found that the forms were ... complex enough to hinder full understanding, according to bioethicists ... of 124 informed-consent documents for U.S. government-sponsored, multinational HIV/AIDS ...
... Rome (July 15, 2011): The Lancet , a leading ... the critical role of expanding access to HIV treatment under ... , The publication of the editorial comment coincides with ... Treatment and Prevention (IAS 2011) taking place in Rome, Italy ...
... An international team of researchers has identified two genetic regions ... Restless legs syndrome is a condition in which people experience ... only by movement. One of the most common neurological diseases, ... and even depression. In the new study, scientists ...
Cached Medicine News:Health News:Nursing home residents at heightened risk of falling in the days following 2Health News:California nurse staffing 2Health News:Injection Drug Users Most in Need of Treatment, Study Says 2Health News:Informed-consent forms should be shortened, simplified, Johns Hopkins bioethicists confirm 2Health News:Informed-consent forms should be shortened, simplified, Johns Hopkins bioethicists confirm 3Health News:Roll out treatment as prevention now to stop HIV and AIDS 2
... comprehensive line of pregnancy tests including rapid ... convenient one-step stick and cassette formats. The ... Easy HCG is a 25 mIU urine ... HCG II provides 25mIU sensitivity for ...
... Wampole Laboratories offers a comprehensive line ... for serum and urine in convenient one-step ... offers 2 testing options. Clearview Easy HCG ... a convenient stick format. Clearview HCG ...
... hemolyzed preparation of whole blood is mixed ... binding cation-exchange resin. During this time, HbAo ... period. a filter separator is used to ... which contains glycohemoglobin. The percent glycohemoglobin is ...
... is the main storage protein for iron. ... shell (apoferritin) composed of heavy and light ... iron oxide and phosphate [1]. Ferritin is ... other body tissues, with major concentrations found ...
Medicine Products: